Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15199950 | 1.00 | KMT2A (0.55) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL15200084 | 0.93 | TLR2 (0.56) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL12928572 | 0.92 | TLR2 (0.60) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL1300995 | 0.92 | TLR2 (0.60) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL30393342 | 0.92 | TLR2 (0.60) | KMT2ATLR2MDM4TP53CASP3 | |
| Hydrochloric Acid SCHEMBL29399128 | 0.91 | TLR2 (0.60) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL10099563 | 0.91 | KMT2A (0.53) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL13445218 | 0.90 | KMT2A (0.57) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL30404089 | 0.90 | KMT2A (0.57) | KMT2ATLR2MDM4TP53CASP3 | |
| SCHEMBL19426629 | 0.90 | KMT2A (0.57) | KMT2ATLR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | KMT2A 3283/4885TLR2 774/4885MDM4 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.